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Summary
 Aim Analysis of classical prognostic factors in patients with non-advanced endometri-
al cancer treated with postoperative radiotherapy.
 Materials/Methods In the years 1985–1999, 705 patients underwent postoperative radiotherapy due 
to endometrial cancer: 529 patients with FIGO stage I and 176 with FIGO stage 
II cancer. Mean age was 58 years. In 96% of patients endometrioid adenocarci-
noma was found. In 49.9% the cancer had a high, in 27.9% a medium, and in 
22.2% a low degree of differentiation.
 Results 82% of patients had 5-year disease-free survival. In univariate analysis a signiﬁ -
cantly higher rate of disease-free survival was observed in: patients younger than 
60, with moderately and well differentiated cancers, with stage I endometrioid 
adenocarcinoma with less than 50% myometrial invasion. In multivariate analysis 
degree of cancer differentiation was the only independent prognostic factor.
 Conclusions In a group of patients with non-advanced endometrial cancer treated with post-
operative radiotherapy, degree of cancer differentiation is the primary prognos-
tic factor.
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BACKGROUND
Surgical treatment is the procedure of choice in 
women with non-advanced endometrial cancer 
[1–4]. Indications for postoperative radiothera-
py are assessed based on a set of prognostic fac-
tors which allow the patient to be qualiﬁ ed to one 
of three groups according to the level of risk of 
recurrence: low-risk, intermediate-risk, or high-
risk [2–4].
Numerous prognostic factors are presented in 
the literature for this group of patients, includ-
ing: age, state of their hormone receptors, stage 
of the cancer according to FIGO, cancer differen-
tiation degree, depth of myometrial invasion, vas-
cular invasion, cervical involvement, cancer type 
based on cellular classiﬁ cation [1,4–0]. However, 
all the authors consistently list only a few of the 
factors, based on multivariate analysis, as having 
independent prognostic value. The detailed lev-
els of prognostic value of these factors are still 
being discussed (e.g. age, degree of differentia-
tion, depth of myometrial invasion).
Sporadically, other prognostic factors are also 
found in the literature, such as weight, ethnicity, 
obstetric history, duration of clinical symptoms, 
and size of the primary tumour [1,4,5,11,12].
A separate group of potential prognostic fac-
tors, currently widely presented and discussed, 
includes markers studied using immunohisto-
chemical, cytoﬂ uorometric and molecular biol-
ogy techniques, e.g. DNA ploidy, proliferation 
index, S-phase fraction, MIB-1 (Ki-67), expres-
sion of p53 and HER 2/neu genes, angiogen-
esis, etc. [1,8,13–17].
AIM
The aim of the present study was the analysis of 
classical prognostic factors in patients with non-
advanced endometrial cancer treated with post-
operative radiotherapy.
MATERIALS AND METHODS
There were 895 patients with endometrial can-
cer treated in the Centre of Oncology in Kraków 
between 1985 and 1999. 752 (84.0%) were diag-
nosed with non-advanced stage I or II cancer ac-
cording to FIGO 1988 staging (18). 47 (5.2%) 
were diagnosed with well or moderately differ-
entiated stage IA cancer; this group was treated 
with surgery alone. The remaining 705 (78.8%) 
patients with endometrial stage IA (poorly differ-
entiated), IB, IC and II were treated with combi-
nation therapy: surgery followed by postoperative 
irradiation; and for this group a detailed analysis 
of classical prognostic factors was performed.
The youngest patient in the study group was 30, 
and the oldest was 80 years old; mean age was 58 
years, median 59 years. Duration of presence of 
symptoms ranged from 1 to 108 months; mean 8 
months, median 4 months. In our group 17.9% 
of women were nulliparous, 15.9% were unipa-
rous, 29.1% biparous and 37.1% had a history of 
3 or more births. In 676 (95.9%) women endome-
trioid adenocarcinoma was found, in 10 (1.4%) 
clear cell cancer, in 8 (1.1%) serous cancer, in 4 
(0.6%) mucinous and in 7 (1.0%) other cancer 
types. 59% of patients had a haemoglobin level 
below 13g/dl, and the remaining 41% had a lev-
el of 13g/dl or higher.
In 75% of patients endometrial stage I cancer 
was found, and among this group: in 21 (3.0%) 
IA, in 180 (25.5%) IB and in 328 (46.5%) IC. 
In 25% of the studied women endometrial stage 
II cancer was found, and among this group: in 
85 (12.1%) IIA, and in 91 (12.9%) IIB. In al-
most half of cases (49.9%) the cancer was well, 
in 27.9% moderately and in 22.2% poorly dif-
ferentiated. In 21 (3.0%) patients invasion of 
the cancer was limited to the endometrium; 
in 297 (42.1%) myometrial invasion was below 
and in 387 (54.9%) was above 50% of myome-
trial thickness.
All patients underwent a classical, total, ab-
dominal hysterectomy with bilateral salpingo-
oophorectomy and postoperative radiotherapy. 
During surgery samples for peritoneal cytolo-
gy were taken. The group of 170 (24.1%) pa-
tients with intermediate risk of recurrence (IA 
G3, IB G1, G2) received teleradiotherapy alone. 
Of 535 (75.9%) patients with high risk of recur-
rence (IB-G3, IC, II) 230 (43%) received vaginal 
brachytherapy alone, and 305 (57%) received 
a combination of teleradiotherapy and vaginal 
brachytherapy.
Five-year disease-free survival after surgery was 
used as an efﬁ cacy measure. Log-rank test accord-
ing to Peto et al. was used for assessment of signif-
icance of the observed differences in the studied 
material [19]. P≤0.05 was taken as the statistical 
signiﬁ cance level. Cox’s proportional hazard mod-
el analysis was used to assess the inﬂ uence of se-
lected factors on survival rate [20].
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RESULTS
Of the 705 patients in the present group, 578 
(82%) had a 5-year disease-free survival period. 
Relations between treatment outcome and de-
mographic, clinical and microscopic features are 
presented in Table 1.
Table 1 shows that univariate analysis in our 
group detects the inﬂ uence of age, cellular type 
of cancer, its differentiation degree and stage 
according to FIGO and depth of myometrial in-
vasion on treatment outcome. A statistically sig-
niﬁ cant higher 5-year disease-free survival rate 
was observed in patients younger than 60 years, 
with moderately and well differentiated cancers 
(G1 vs. G2 vs. G3), endometrioid adenocarcino-
ma (vs. other cancer types) in stage I (I vs. II), 
with less than 50% myometrial invasion. Parity 
and haemoglobin level did not display a signiﬁ -
cant inﬂ uence on treatment outcome in univar-
iate analysis.
Results of multivariate analysis according to Cox 
are presented in Table 2.
In the studied group of patients with endometri-
al cancer, treated with surgery followed by post-
operative irradiation, degree of cancer differ-
entiation was the only independent prognostic 
factor for 5-year disease-free survival in multivar-
iate analysis.
DISCUSSION
Multivariate analysis of prognostic factors in the 
group of 705 patients with non-advanced en-
dometrial cancer, undergoing surgery followed 
by radiotherapy, was performed. Degree of can-
cer differentiation turned out to be the only in-
dependent prognostic factor. 90.9% of patients 
with well (G1), 80.2% with moderately (G2), and 
64.1% with poorly (G3) differentiated cancer sur-
vived 5 years with no evidence of the disease.
These results are in accordance with the data 
from the literature, where the degree of can-
cer differentiation is unequivocally described 
as one of the primary factors inﬂ uencing prog-
nosis in patients with endometrial cancer 
[1,5–8,11,13,17,21–25].
Spaczyński et al. reported an 80% success rate in 
patients with well (G1), 74% moderately (G2) and 
50% with poorly (G3) differentiated endometri-
al cancer [1]. Di Saia and Creasman reported: 
Demographic,
clinical and microscopic 
features
Number 
of
treated 
patients
5-year
disease-free survival
Number of 
patients %
Age*:
 below 60 years
 60 and more years
366
339
315
263
86.1
77.6
Parity:
 nulliparous
 uniparous
 biparous
 3 or more births
126
112
205
262
103
92
168
215
81.7
82.1
82.0
82.1
Duration of symptoms’ 
presence:
 below 6 months
 6 months and more
330
375
270
308
81.8
82.1
Cellular cancer type*:
 endometrioid 
adenocarcinoma
 other
676
29
561
17
83.0
58.6
Haemoglobin level (g/dl):
 below 13
 13 and more
416
289
342
236
82.2
81.7
Cancer staging according to 
FIGO (1988)*:
 IA
 IB
 IC
 IIA
 IIB
21
180
328
85
91
16
169
279
64
50
76.2
93.9
85.1
75.3
54.9
Cancer diff erentiation degree (G)*:
 G1
 G2
 G3
352
197
156
320
158
100
90.9
80.2
64.1
Depth of cancer myometrial 
invasion*:
 no invasion
 less than 50%
 more than 50%
21
297
387
16
261
301
76.2
87.9
77.8
Sum 705 578 82.0
* Diff erence statistically signifi cant, log rank test: p≤0.05.
Table 1. Treatment outcome in relation to demographic, clinical 
and microscopic features.
Feature Relative risk Signifi cance p
Cancer diff erentiation degree: 
 high (G1)
 medium (G2)
 low (G3)
1.00
1.65
2.48
0.0029
0.0004
Table 2. Multivariate analysis results.
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94%, 88% and 79% success rates, and Zaino et al. 
in a group of 597 patients: 91%, 82% and 66%, 
respectively [5,6]. Hachirsuga et al. described 
10-year survival in 95% with well and 84% and 
64% with moderately and poorly differentiated 
endometrial cancer, respectively [22]. Petterson 
in “Annual report on the results of treatment in 
gynecological cancer” from 1994 reported the fol-
lowing rates of 5-year survival in relation to dif-
ferentiation degree of the endometrial cancer: 
in I – 89%, 82% and 69% (G1 vs. G2 vs. G3); in 
II – 75%, 65% and 52% [23]. Other authors re-
ported success rates in stage I endometrial can-
cer ranging from 91% to 98% in well differen-
tiated cancers, from 82% to 90% in moderately 
differentiated cancers and from 64% to 80% in 
poorly differentiated cancers [5,6,22].
Overall it is stressed in the literature that the low-
er differentiation degree, the higher probability of 
deep myometrial invasion and of extrauterine in-
volvement [5,13,21,24,25]. Cheon et al. observed 
deep myometrial invasion in 12% of 210 patients 
with well differentiated cancer (G1), in 20% of 74 
patients with moderately and in 46% of 70 patients 
with poorly differentiated cancer [26]. In GOG 
studies, Creasman et al. observed 23% of cases of 
myometrial invasion exceeding 2/3 of myometrial 
thickness in the group with well differentiated can-
cer and 58% in the group with poorly differentiated 
cancer [21]. Di Saia and Creasman reported 10%, 
20% and 42% cases of deep myometrial invasion in 
patients with well, moderately and poorly differen-
tiated endometrial cancer, respectively [5].
Degree of cancer differentiation inﬂ uences sig-
niﬁ cantly the probability of local lymph node in-
volvement. Morrow reported that in his group of 
70 patients with poorly differentiated cancer pelvic 
lymph node involvement was observed in 21.4% of 
cases, and of 440 patients with moderately and well 
differentiated cancer only in 4.1% [27]. Bonnier et 
al. observed pelvic lymph node metastases in 2–3% 
of patients with well differentiated, 10–15% with 
moderately and 18–25% with poorly differentiat-
ed stage I and II endometrial cancer [28].
It should be stressed that many authors consider 
moderate and especially poor differentiation de-
gree as the primary indication for adjuvant, post-
operative radiotherapy in patients with non-ad-
vanced endometrial cancer [6,9,29,30].
Univariate analysis showed that in the present 
group women younger than 60 years had a bet-
ter prognosis compared to older patients. Data 
from the literature quite unequivocally point to 
worse prognosis in older women, although there 
are differences in assessment of prognostic age 
cut-off with a range between 60 and 70 years 
[1,6,7,9,11,17,23–25,31].
In our group the highest 5-year disease-free sur-
vival rate was observed in patients with endome-
trioid adenocarcinoma compared to other cellu-
lar cancer types [83.0% vs. 58.6%]. The literature 
reports emphasize the particularly bad progno-
sis in patients with clear cell cancer, and serous 
cancer [1,5,6,9,25,32]. Ziano et al. in a group of 
597 subjects reported 5-year disease-free surviv-
al in: 82% of patients with endometrioid adeno-
carcinoma, 68% with clear cell cancer and 55% 
with serous cancer [6].
Undoubtedly, differentiation degree of the can-
cer is the primary prognostic factor in patients 
with endometrial cancer. In the present group 
the rate of 5-year disease-free survival decreased 
with the cancer stage [IB vs. IC vs. IIA vs. IIB], 
reaching: 93.9%, 85.1%, 75.3% and 54.9%, re-
spectively. Altogether, of patients with stage I can-
cer 87.7% survived a 5-year disease-free period, 
and with stage II cancer, 64.8%; the difference 
was statistically signiﬁ cant.
Di Saia and Creasman report 86% 5-year surviv-
al for endometrial cancer in stage I and 66% in 
stage II [5]. Cicaric et al. described 93.5% 5-year 
survival in patients with stage IB cancer, 80.4% in 
stage IC and 82.8% in stage II [33]. Weiss et al. 
report 92% 5-year disease-free survival in patients 
with stage IA and IB cancers, 84% with stage IC 
and 79% with stage II [34].
In the present group depth of myometrial inva-
sion was a prognostic factor, but only in the uni-
variate analysis; the 5-year disease-free survival 
rate was signiﬁ cantly lower in patients with my-
ometrial invasion of more than 50% of the my-
ometrium thickness, compared to patients with 
lower degree of myometrial involvement [77.8% 
vs. 87.1%]. Based on data from the literature 
the depth of myometrial invasion is an estab-
lished prognostic factor; deep invasion is con-
nected with higher staging degree, with cellular 
types of cancer with poorer prognosis, and also 
with higher rate of pelvic lymph nodes metastas-
es [1,6,9,13,17,21–26,28,35].
The studies on improvement of treatment ef-
ﬁ cacy in non-advanced endometrial cancer 
concentrate on several issues: improvement of 
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systemic treatment , as the most frequent reason 
for therapeutic failure is the spreading of the dis-
ease [new medications research]; improvement 
of radiotherapy [conformal radiotherapy, uncon-
ventional fractionation radiotherapy, radiosensi-
tivity tests]; and search of biological factors ena-
bling identiﬁ cation of patient groups with high 
recurrence risk – biological prognostic factors 
[1,5,8,13,14,16,31,36–40].
CONCLUSIONS
In a group of patients with non-advanced en-
dometrial cancer treated with postoperative ra-
diotherapy, degree of cancer differentiation is 
the primary prognostic factor.
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